Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Apr 23

PMID 35454927

Authors

Marta Malczewska

Kamil Kosmider

Kinga Bednarz

Katarzyna Ostapinska

Monika Lejman

Joanna Zawitkowska

Affiliations

Soon will be listed here.

Abstract

Acute lymphoblastic leukemia is the most common blood cancer in pediatric patients. There has been enormous progress in ALL treatment in recent years, which is reflected by the increase in the 5-year OS from 57% in the 1970s to up to 96% in the most recent studies. ALL treatment is based primarily on conventional methods, which include chemotherapy and radiotherapy. Their main weakness is severe toxicity, which prompts dose reduction, decreases the effectiveness of the treatment, and, in some cases, can lead to death. Currently, numerous modifications in treatment regimens are applied in order to limit toxicities emerging from conventional approaches and improve outcomes. Hematological treatment of pediatric patients is reaching for more novel treatment options, such as targeted treatment, CAR-T-cells therapy, and immunotherapy. These methods are currently used in conjunction with chemotherapy. Nevertheless, the swift progress in their development and increasing efficacity can lead to applying those novel therapies as standalone therapeutic options for pediatric ALL.

Citing Articles

Artificial Intelligence Powered Automated and Early Diagnosis of Acute Lymphoblastic Leukemia Cancer in Histopathological Images: A Robust SqueezeNet-Enhanced Machine Learning Framework.

Mehan V Int J Telemed Appl. 2025; 2025:2257215.

PMID: 40017574 PMC: 11867728. DOI: 10.1155/ijta/2257215.

Circulating lncRNA HOTAIR is a biomarker for pediatric acute lymphoblastic leukemia and mediator of miR-326 exosomal export.

Dashti N, Fadavi D, Rezaei R, Rahgozar S, Moafi A Sci Rep. 2025; 15(1):4901.

PMID: 39929912 PMC: 11811015. DOI: 10.1038/s41598-025-87857-0.

The Impact of Interactive Video Games Training on the Quality of Life of Children Treated for Leukemia.

Kowaluk A, Malicka I, Kalwak K, Wozniewski M Cancers (Basel). 2024; 16(21).

PMID: 39518038 PMC: 11545673. DOI: 10.3390/cancers16213599.

Paediatric Acute Lymphoblastic Leukaemia: A Narrative Review of Current Knowledge and Advancements.

Elgazar S, Constantinou C Curr Oncol Rep. 2024; 26(12):1586-1599.

PMID: 39503990 DOI: 10.1007/s11912-024-01608-4.

Infections in Children with Acute Lymphoblastic Leukemia.

Segulja S, Vranesevic K, dordevic A, Roganovic J Medicina (Kaunas). 2024; 60(9).

PMID: 39336436 PMC: 11434315. DOI: 10.3390/medicina60091395.

References

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

Sutton R, Shaw P, Venn N, Law T, Dissanayake A, Kilo T . Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol. 2014; 168(3):395-404. DOI: 10.1111/bjh.13142. View

Biondi A, Gandemer V, De Lorenzo P, Cario G, Campbell M, Castor A . Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol. 2018; 5(12):e641-e652. DOI: 10.1016/S2352-3026(18)30173-X. View

Pieters R, de Groot-Kruseman H, van der Velden V, Fiocco M, van den Berg H, de Bont E . Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016; 34(22):2591-601. DOI: 10.1200/JCO.2015.64.6364. View

McAtee C, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M . Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open. 2021; 4(2):e2036321. PMC: 7859842. DOI: 10.1001/jamanetworkopen.2020.36321. View

Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R . Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013; 14(3):199-209. DOI: 10.1016/S1470-2045(12)70600-9. View

Winter S, Dunsmore K, Devidas M, Wood B, Esiashvili N, Chen Z . Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018; 36(29):2926-2934. PMC: 6366301. DOI: 10.1200/JCO.2018.77.7250. View

Malard F, Mohty M . Acute lymphoblastic leukaemia. Lancet. 2020; 395(10230):1146-1162. DOI: 10.1016/S0140-6736(19)33018-1. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

10.

Fagioli F, Quarello P, Zecca M, Lanino E, Rognoni C, Balduzzi A . Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Haematologica. 2013; 98(8):1273-81. PMC: 3729909. DOI: 10.3324/haematol.2012.079707. View

11.

Inaba H, Mullighan C . Pediatric acute lymphoblastic leukemia. Haematologica. 2020; 105(11):2524-2539. PMC: 7604619. DOI: 10.3324/haematol.2020.247031. View

12.

Maude S, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A . Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015; 125(11):1759-67. PMC: 4357583. DOI: 10.1182/blood-2014-06-580480. View

13.

Wei G, Wang J, Huang H, Zhao Y . Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017; 10(1):150. PMC: 5563021. DOI: 10.1186/s13045-017-0516-x. View

14.

Lee J, Cho B . Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. Korean J Pediatr. 2017; 60(5):129-137. PMC: 5461276. DOI: 10.3345/kjp.2017.60.5.129. View

15.

Inaba H, Pui C . Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010; 11(11):1096-106. PMC: 3309707. DOI: 10.1016/S1470-2045(10)70114-5. View

16.

Yi M, Zhou L, Li A, Luo S, Wu K . Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. Aging (Albany NY). 2020; 12(22):22869-22891. PMC: 7746341. DOI: 10.18632/aging.103982. View

17.

Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W . Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol. 2021; 39(30):3340-3351. DOI: 10.1200/JCO.21.00389. View

18.

Zhang X, Lu X, Yang J, Zhang G, Li J, Song L . Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020; 4(10):2325-2338. PMC: 7252549. DOI: 10.1182/bloodadvances.2020001466. View

19.

Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O . Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014; 4:e252. PMC: 4220650. DOI: 10.1038/bcj.2014.72. View

20.

Chazen G, Pereira G, Legros G, Gillis S, Shevach E . Interleukin 7 is a T-cell growth factor. Proc Natl Acad Sci U S A. 1989; 86(15):5923-7. PMC: 297743. DOI: 10.1073/pnas.86.15.5923. View